Physician profile
James E Greer
NPI 1548268303
$780,128.89
in general payments reported to CMS, 2019-2025
20 companies · $176K in 2025
The $176K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $48K · 2021: $55K · 2022: $126K · 2023: $116K · 2024: $178K · 2025: $176K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $365K · Consulting Fee: $55K · Travel and Lodging: $31K · Food and Beverage: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $365,123.00 |
| Consulting Fee | $54,768.50 |
| Travel and Lodging | $31,023.40 |
| Food and Beverage | $19,458.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $214,579.10 | 2019-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123,572.69 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $104,190.94 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $84,714.29 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $84,000.08 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $62,546.19 | 2024-2025 | Fanapt |
| Abbvie INC. | $40,544.13 | 2021-2024 | |
| Allergan, INC. | $25,773.72 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $20,209.97 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $9,791.79 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $8,201.63 | 2021-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $540.34 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $469.24 | 2019-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $397.12 | 2019-2021 | |
| Corium, LLC | $317.74 | 2022-2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evolution Surgical, INC | $99.78 | 2021 | |
| Indivior INC. | $68.24 | 2023-2025 | Sublocade, Perseris |
| Shire North American Group INC | $53.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.76 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $17.14 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.